The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...

What Is Pulmonary Vascular Disease? The definition of pulmonary vascular disease is simple: any condition that affects the blood vessels along the route between the heart and lungs. Blood travels from ...

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.

Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study showed ...

Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...

HOUSTON, October 13, 2025--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule ...

The FDA has approved Boehringer Ingelheim's nerandomilast as a treatment for idiopathic pulmonary fibrosis (IPF), giving the company a successor to its blockbuster therapy Ofev. Phosphodiesterase (PDE ...

Using 21 st century diagnostics to overcome barriers for lung function testing in primary care: it is time to consider oscillometry Obstructive airways diseases, including asthma and COPD as the most ...

An office breathing test typically means you blow into a machine that measures how much air your lungs can take in and how quickly and forcefully you can blow it out. These numbers tell your doctor if ...